These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 6478648)

  • 21. Cyclophosphamide intensifies the acquisition of allergic contact dermatitis in mice rendered B-cell deficient by heterologous anti-IgM antisera.
    Maguire HC; Faris L; Weidanz W
    Immunology; 1979 Jun; 37(2):367-72. PubMed ID: 313902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunological aspects of contact sensitivity.
    Polak L
    Monogr Allergy; 1980; 15():1-170. PubMed ID: 6444240
    [No Abstract]   [Full Text] [Related]  

  • 23. Induction of contact sensitivity and antigenic competition by the intravenous administration of contact sensitizers.
    Nakano Y; Nakano K
    Immunology; 1981 Jan; 42(1):111-8. PubMed ID: 7461721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suppression of delayed hypersensitivity to tuberculin by antigenic competition. A positive immunoregulatory mechanism sensitive to cyclophosphamide.
    Dwyer JM; Parker D; Turk JL
    Immunology; 1981 Apr; 42(4):549-59. PubMed ID: 6453829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low zone tolerance induced by systemic application of allergens inhibits Tc1-mediated skin inflammation.
    Seidel-Guyenot W; Perschon S; Dechant N; Alt R; Knop J; Steinbrink K
    J Allergy Clin Immunol; 2006 May; 117(5):1170-7. PubMed ID: 16675348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B cells are not required for T cell priming in low zone tolerance to contact allergens and contact hypersensitivity.
    Seidel-Guyenot W; Alt R; Perschon S; Knop J; Steinbrink K
    Eur J Immunol; 2004 Nov; 34(11):3082-90. PubMed ID: 15376190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistent activity of suppressor cells in T cell-mediated immune response.
    Polak L; Rinck C
    J Immunol; 1978 Aug; 121(2):762-6. PubMed ID: 308079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of selected immunomodulating agents on experimental contact reactions.
    Anderson C
    Acta Derm Venereol Suppl (Stockh); 1985; 116():1-48. PubMed ID: 3901646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose cyclophosphamide inhibits anterior chamber-associated immune deviation (ACAID) and the production of extracellular antigen-specific T cell proteins induced by trinitrophenylated (TNP) spleen cells.
    Wang Y; O'Rourke J; Cone RE
    Cell Immunol; 1995 Oct; 165(2):284-8. PubMed ID: 7553893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Local administration of cytostatic drugs enhances delayed-type hypersensitivity to Sendai virus in mice.
    Limpens J; Garssen J; Scheper RJ
    Clin Immunol Immunopathol; 1990 Jan; 54(1):161-5. PubMed ID: 2152858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postburn immunosuppression in an animal model. II. Restoration of cell-mediated immunity by immunomodulating drugs.
    Hansbrough J; Peterson V; Zapata-Sirvent R; Claman HN
    Surgery; 1984 Mar; 95(3):290-6. PubMed ID: 6322373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence that X-irradiation and 4-hydroperoxycyclophosphamide affects different lymphocytes that respond to specific antigen in vitro.
    Clark C; LaSota I; Borch RF
    J Leukoc Biol; 1985 Feb; 37(2):175-91. PubMed ID: 2578536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclophosphamide suppression of established cell-mediated immunity. Quantitative vs. qualitative changes in lymphocyte populations.
    Balow JE; Hurley DL; Fauci AS
    J Clin Invest; 1975 Jul; 56(1):65-70. PubMed ID: 1095612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Enhanced immunogenicity of xenogenized tumor cells in rats pretreated with cyclophosphamide (author's transl)].
    Terashima M
    Hokkaido Igaku Zasshi; 1980 Nov; 55(6):495-9. PubMed ID: 6456215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide.
    Berd D; Maguire HC; Mastrangelo MJ
    Cancer Res; 1984 Nov; 44(11):5439-43. PubMed ID: 6488195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of cyclophosphamide on immunological control mechanisms.
    Turk JL; Parker D
    Immunol Rev; 1982; 65():99-113. PubMed ID: 6214496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of millimeter waves on cyclophosphamide induced suppression of the immune system.
    Logani MK; Anga A; Szabo I; Agelan A; Irizarry AR; Ziskin MC
    Bioelectromagnetics; 2002 Dec; 23(8):614-21. PubMed ID: 12395417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of cyclophosphamide-induced eosinophilia in contact sensitivity: functional roles of interleukin-5-producing CD4(+) lymphocytes.
    Sasaki G; Satoh T; Yokozeki H; Katayama I; Nishioka K
    Cell Immunol; 2000 Aug; 203(2):124-33. PubMed ID: 11006010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of the direct effects of cyclophosphamide on cell-mediated immunological responses.
    Balow JE; Parrillo JE; Fauci AS
    Immunology; 1977 Jun; 32(6):899-904. PubMed ID: 328385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.